Summit completes subject enrolment in Phase III NSCLC treatment trial [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
trial of ivonescimab, along with platinum-doublet chemotherapy for the treatment of a certain type of non-small cell lung cancer (NSCLC). Patients from North America, Europe, and China are part of the multi-regional trial. The trial includes individuals with epidermal growth factor receptor-mutated (EGFRm), locally advanced or metastatic non-squamous NSCLC, whose disease advanced following third-generation EGFR tyrosine kinase inhibitor (TKI) therapy. This patient population is said to have previously seen unsuccessful results from PD-1 monoclonal antibodies in Phase III global trials, the company noted. The HARMONi trial will compare the efficacy of ivonescimab plus platinum-doublet chemotherapy against a placebo plus platinum-doublet chemotherapy. Designed with dual primary endpoints, the HARMONi trial aims to evaluate progression-free survival and overall survival. The company anticipates topline data from the HARMONi trial in mid-2025. Furthermore, the US Food and Dr
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics (SMMT) Hurt Bronte Capital. Here's Why [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
- Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 10/30/24 - Beat
SMMT
Sec Filings
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- 10/15/24 - Form 4
- SMMT's page on the SEC website